FDA OKs Bayer’s Gadavist contrast agent

The FDA has approved Bayer’s (OTCPK:BAYRY -0.4%) Gadavist (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion and late gadolinium enhancement in adult patients with known or suspected coronary artery disease. The company says it is the only contrast agent approved in the U.S. for use in cardiac MR.

https://seekingalpha.com/news/3477749-fda-oks-bayers-gadavist-contrast-agent